Amifostine for salivary glands in high-dose radioactive iodine treated differentiated thyroid cancer

Ma, Chao; Xie, Junxia; Chen, Yi‐Ping Phoebe; Wang, Guo‐Ming; Zuo, Shi

doi:10.1002/14651858.cd007956.pub2

Cited by 17 publications

(13 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These findings were also in agreement with those of Ma et al [20]. The beneficial cytoprotective effect of amifostine might have been obscured by the dose effects of radioiodine.…”

Section: Discussionsupporting

confidence: 93%

A Systematic Review of Adjuvant Interventions for Radioiodine in Patients with Thyroid Cancer

Ge³

et al. 2015

Oncol Res Treat

View full text Add to dashboard Cite

Aims: The purpose of this study was to assess the effects of adjuvant interventions for radioiodine in patients with thyroid cancer. Materials and Methods: A systematic search was undertaken on July 9, 2014. RevMan 5 software was used to synthesize data. Results: 13 randomized controlled trials were included. The pooled risk ratio of 0.99 (95% confidence interval (CI): 0.96-1.02, p = 0.58) indicated no significant difference in successful thyroid remnant ablation between recombinant human thyroid-stimulating hormone (rhTSH) and thyroid hormone withdrawal in 7 trials. The percentage of patients who had successful ablation was significantly higher in the oral-lithium group than in the control group (p = 0.017). A computerized decision aid improves informed decision-making in patients with early-stage papillary thyroid cancer (PTC) who are considering adjuvant radioiodine treatment (p < 0.001). Amifostine pretreatment did not prevent parenchymal damage to the major salivary gland function after radioiodine treatment (p = 0.2461). Conclusions: The present systematic review suggests that rhTSH, lithium, and computerized decision aids maybe act as beneficial adjuvant interventions for radioiodine in patients with thyroid cancer; however, amifostine does not exhibit helpful effects in thyroid cancer patients treated with radioiodine.

show abstract

“…These findings were also in agreement with those of Ma et al [20]. The beneficial cytoprotective effect of amifostine might have been obscured by the dose effects of radioiodine.…”

Section: Discussionsupporting

confidence: 93%

A Systematic Review of Adjuvant Interventions for Radioiodine in Patients with Thyroid Cancer

Ge³

et al. 2015

Oncol Res Treat

View full text Add to dashboard Cite

show abstract

“…11,22 In addition, its beneficial effects in patients with thyroid cancer undergoing 131 I therapy are yet to be established. 12,13 Hence, the major focus of our experiment was to develop a better radioprotectant for the salivary gland against therapeutic 131 I exposure that would be nontoxic and highly effective. Our earlier work in mice had given us encouraging preliminary results for salivary gland radioprotection against 3.7 MBq of 131 I exposure for 24 hours by using O. sanctum presupplementation.…”

Section: Discussionmentioning

confidence: 99%

“…8,11 Limited studies have reported the usage of amifostine against internal radioiodine exposure in differentiated thyroid carcinoma and with controversial results. 7,12,13 At present, many traditional ayurvedic herbal formulations, plant extracts alone or in combination, are being explored for their efficacy against radiation-induced cell damage. Among them, Ocimum sanctum, a medicinal plant in India, is known to have various beneficial effects including radioprotection against 60 Co gamma radiation.…”

Section: Introductionmentioning

confidence: 99%

Radioprotective Effect of Ocimum sanctum and Amifostine on the Salivary Gland of Rats After Therapeutic Radioiodine Exposure

Joseph

Bhartiya

Raut

et al. 2011

Cancer Biotherapy and Radiopharmaceuticals

View full text Add to dashboard Cite

The current study investigated the radioprotective effect of Ocimum sanctum on the salivary gland of rats administered radioiodine ((131)I) and compared its efficacy with a known radioprotectant, amifostine. The experimental rats were divided in four groups and sacrificed in three different batches at 1, 3, and 6 months of time interval after 18.5 MBq/100g (i.p.) (131)I exposure. Six months duration batch received (131)I exposure twice with the gap of 3 months. Two groups of experimental rats were presupplemented with O. sanctum (40 mg/kg for 5 days, orally) and amifostine (200 mg/kg, s.c) before (131)I exposure separately. Increased Technetium-99m-pertechnetate ((99m)TcO(4)(-)) uptake at 30 minutes post injection in salivary glands of only (131)I exposed rats may imply delay in clearance at 6 months of exposure in comparison to their counterparts sacrificed at 1 month. Parotid gland histology showed atrophy with lipomatosis in only (131)I exposed rats at 3 and 6 months of duration. O. sanctum and amifostine presupplemented and subsequently exposed to (131)I rats at 3 and 6 months duration exhibited comparable histopathology with controls. Our study indicates possible radioprotective effect of O. sanctum and amifostine against high-dose (131)I exposure.

show abstract

“…Amifostine is a cytoprotective agent that showed initial success at attenuating salivary gland toxicity of 131 I therapy in preclinical and early clinical investigations (Bohuslavizki et al., ; Kutta et al., ). However, with unclear evidence of radioprotection in randomized controlled clinical trials (Kim et al., ; Ma, Xie, Chen, Wang, & Zuo, ; Ma, Xie, Jiang, Wang, & Zuo, ), additional studies are warranted to confirm or refute its benefits. Usefulness of salivary endoscopy (sialendoscopy) in relieving obstructive symptoms and improving salivary flow in 131 I‐induced sialadenitis was demonstrated in previous studies (Nahlieli & Nazarian, ; Strychowsky, Sommer, Gupta, Cohen, & Nahlieli, ).…”

Section: Treatment Of Salivary Gland Dysfunctionmentioning

confidence: 99%

Radioactive iodine: An unappreciated threat to salivary gland function

Sunavala‐Dossabhoy

2018

Oral Diseases

View full text Add to dashboard Cite

Thyroid cancer is an endocrine malignancy whose prevalence is increasing in the United States. Nearly 57,000 new cases of thyroid cancer are estimated to be diagnosed in 2017. The standard of care for differentiated thyroid cancer is thyroidectomy followed by ablation of thyroid remnants with high-dose radioactive iodine ( I). Apart from thyroid glands, I accumulates in cells of salivary glands and compromises its function. Xerostomia is, therefore, a frequent and often persistent complaint of patients. Despite adoption of standard preventive measures, parenchymal damage and chronic salivary dysfunction are observed in a substantial number of patients. Saliva is important for oral homeostasis, and its reduction increases the risk of oral morbidity. As differentiated thyroid cancer patients have an excellent survival rate, preservation of salivary gland function carries added significance. A focus on treatments that preserve or restore long-term salivary flow can significantly improve the quality of life of thyroid cancer survivors.

show abstract

Amifostine for salivary glands in high-dose radioactive iodine treated differentiated thyroid cancer

Abstract: Amifostine for salivary glands in high-dose radioactive iodine treated di erentiated thyroid cancer (Review)

Cited by 17 publications

References 60 publications

A Systematic Review of Adjuvant Interventions for Radioiodine in Patients with Thyroid Cancer

A Systematic Review of Adjuvant Interventions for Radioiodine in Patients with Thyroid Cancer

Radioprotective Effect of Ocimum sanctum and Amifostine on the Salivary Gland of Rats After Therapeutic Radioiodine Exposure

Radioactive iodine: An unappreciated threat to salivary gland function

Contact Info

Product

Resources

About